Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer
Shuxia Qin, Lidan Yi, Sini Li, Chongqing Tan, Xiaohui Zeng, Liting Wang, Peng Ye, Xiaomin Wan
Topics & Concepts
AtezolizumabMedicineOncologyPlaceboCost effectivenessHazard ratioInternal medicineChemotherapyQuality-adjusted life yearImmunotherapyCancerConfidence intervalPembrolizumabPathologyRisk analysis (engineering)Alternative medicineBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersRenal cell carcinoma treatment